377
Participants
Start Date
July 27, 2021
Primary Completion Date
December 20, 2023
Study Completion Date
December 20, 2023
Tislelizumab
200 mg intravenously once every 3 weeks
Docetaxel
75 mg/m\^2 intravenously once every 3 weeks
Sitravatinib
100 mg orally once daily
Blacktown Cancer and Haematology Centre, Blacktown
St George Hospital, Kogarah
The Tweed Valley Hospital, Cudgen
Campbelltown Hospital, Campbelltown
Sunshine Hospital, St Albans
St Vincents Hospital Melbourne, Fitzroy
Monash Health, Clayton
Pindara Private Hospital, Benowa
Cancer Research South Australia, Adelaide
Beijing Cancer Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Liaoning Cancer Hospital and Institute, Shenyang
First Affiliated Hospital of Dalian Medical University, Dalian
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai
Affiliated Zhongshan Hospital of Fudan University, Shanghai
Huashan Hospital Affiliated to Fudan University, Shanghai
Nanjing First Hospital, Nanjing
Zhongda Hospital Southeast University, Nanjing
Changzhou No Peoples Hospital, the Affiliated Hospital of Nanjing Medical University Branch Cheng, Changzhou
The Second Affiliated Hospital of Soochow University, Suzhou
The First Affiliated Hospital of Soochow University, Suzhou
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei
Jinan Central Hospital, Jinan
Shandong Cancer Hospital, Jinan
The Affiliated Hospital of Qingdao University Branch Laoshan, Qingdao
Tianjin Medical University General Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Taizhou Hospital of Zhejiang, Taizhou
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
The Second Affiliated Hospital of Nanchang University, Nanchang
Fujian Provincial Hospital, Fuzhou
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing
Daping Hospital, Third Military Medical University, Chongqing
The Second Xiangya Hospital of Central South University, Changsha
The First Peoples Hospital of Chenzhou, Chenzhou
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
Hubei Cancer Hospital, Wuhan
The Second Hospital, University of South China, Hengyang
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Cancer Center of Guangzhou Medical University, Guangzhou
Guangdong Provincial Peoples Hospital, Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
Cancer Hospital of Shantou University Medical College, Shantou
Cancer Hospital Chinse Academy of Medical Sciences, Shenzhen Center, Shenzhen
The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Sichuan Cancer Hospital and Institute, Chengdu
West China Hospital, Sichuan University, Chengdu
Yunnan Cancer Hospital, Kunming
The First Hospital of Lanzhou University, Lanzhou
General Hospital of Ningxia Medical University, Yinchuan
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi
Lead Sponsor
BeiGene
INDUSTRY